Abatacept Improves Overall Health in dcSSc, but Fails To Reduce Skin Thickening, Study Finds
Abatacept, a potential treatment for people with early-stage diffuse cutaneous systemic sclerosis (dcSSc), showed clinically significant improvements in patients’ functional ability and overall health, despite failing to significantly reduce skin thickening, a Phase 2 study concluded. The study, “Abatacept…